Senate Health Cmte. Chairman Enzi Addresses FDLI April 7
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA drug safety issues are expected to highlight both Enzi’s and Commissioner-nominee Crawford’s keynote presentations. Additional speakers at the regulatory group’s annual meeting include CMS Administrator McClellan, HHS General Counsel Azar.
You may also be interested in...
House Appropriations Subcommittee Plans FDA Hearing July 26
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.
Second Quarter Earnings Season Heats Up
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.
Project BioShield Is Topic Of House Hearings July 12 And 14
Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.